Sonepcizumab, the monoclonal antibody against S1P that inhibits tumor growth in xenograft models [203], was not an effective S1P blockade in clinical trials for solid tumors [204], emphasizing the need for combinatorial therapies for sphingolipid-based drugs in developing an effective anticancer treatment. This evidence concerns the gene MBTPS1 and neoplasm.